Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the flow of biologic-ready elastomer stoppers through West Pharmaceutical Services’ global plants can mean wading through hundreds of technical pages. Every 10-K and 10-Q dissects proprietary component revenue, capital outlays for clean-room expansions, and inspection findings in dense legal language. If you have ever searched “West Pharmaceutical Services SEC filings explained simply,” you are not alone. Stock Titan’s AI-powered summaries translate those disclosures into clear briefs, spotlighting where injectable-device demand, raw-material costs, and supply-chain risks actually move the numbers.
Need fresh data before the market reacts? Our platform streams West Pharmaceutical Services quarterly earnings report 10-Q filing alerts the moment they hit EDGAR, along with real-time West Pharmaceutical Services Form 4 insider transactions. One click reveals segment margins, R&D on wearable auto-injectors, and pension impacts. For governance questions such as “West Pharmaceutical Services proxy statement executive compensation,” side-by-side charts show how leadership pay ties to total shareholder return, while our natural-language engine highlights any red flags.
From West Pharmaceutical Services annual report 10-K simplified to West Pharmaceutical Services 8-K material events explained, we cover every disclosure so you can:
- Monitor West Pharmaceutical Services insider trading Form 4 transactions before material events
- Compare contract-manufacturing growth across fiscal years
- Flag supply-agreement announcements in 8-K filings
Whether you’re reviewing West Pharmaceutical Services earnings report filing analysis or tracking West Pharmaceutical Services executive stock transactions Form 4, Stock Titan delivers expert insight, real-time updates, and searchable archives—giving you clarity without the clutter.
West Pharmaceutical Services, Inc. (WST) – Form 4 insider filing
On 30 June 2025, director Janet Brutschea Haugen reported an equity-based compensation transaction:
- 58 Phantom Stock Units (deferred share equivalents) were acquired (Code A) at an indicated reference price of $218.80 per unit.
- Following the award, Haugen now holds 114.06 phantom units and 1,318.4 common shares, all in direct ownership.
Phantom units convert to common stock only after the director leaves the board, indicating a long-term alignment of interests rather than an immediate open-market purchase or sale. No common-stock transactions were reported, and the filing does not reference any Rule 10b5-1 trading plan.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
What is the core business of West Pharmaceutical Services?
Which product segments does West operate in?
How does West ensure product quality and regulatory compliance?
What markets does West Pharmaceutical Services serve?
What are some key technologies and innovations associated with West?
How does West differentiate itself from competitors in the pharmaceutical packaging industry?
What role do strategic partnerships play in West's business model?
How does West address the varying needs of its international markets?
What types of injectable therapies does West support?
